title: N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers.
abstract: Numerous G protein-coupled receptors (GPCRs) have been shown to form heteromeric receptors in cell-based assays. Among the many heteromers reported in the opioid receptor family are μ/κ, κ/δ, and μ/δ. However, the in vivo physiological and behavioral relevance for the proposed heteromers have not yet been established. Here we report a unique example of a ligand, N-naphthoyl-β-naltrexamine (NNTA) that selectively activates heteromeric μ/κ-opioid receptors in HEK-293 cells and induces potent antinociception in mice. NNTA was an exceptionally potent agonist in cells expressing μ/κ-opioid receptors. Intriguingly, it was found to be a potent antagonist in cells expressing only μ-receptors. In the mouse tail-flick assay, intrathecal (i.t.) NNTA produced antinociception that was ~100-fold greater than by intracerebroventricular (i.c.v.) administration. The κ-antagonist, norBNI, decreased the i.t. potency, and the activity was virtually abolished in μ-opioid receptor knockout mice. No tolerance was induced i.t., but marginal tolerance (3-fold) was observed via the i.c.v. route. Moreover, NNTA produced neither significant physical dependence nor place preference in the ED50 dose range. Taken together, this work provides an important pharmacologic tool for investigating the in vivo functional relevance of heteromeric μ/κ-opioid receptors and suggests an approach to potent analgesics with fewer deleterious side effects.
authors.affiliation: Department of Medicinal Chemistry, College of Pharmacy, Medical School, University of Minnesota, Minneapolis, MN 55455, USA.
authors.forename: Ajay S
authors.initials: AS
authors.lastname: Yekkirala
authors.forename: Mary M
authors.initials: MM
authors.lastname: Lunzer
authors.forename: Christopher R
authors.initials: CR
authors.lastname: McCurdy
authors.forename: Michael D
authors.initials: MD
authors.lastname: Powers
authors.forename: Alexander E
authors.initials: AE
authors.lastname: Kalyuzhny
authors.forename: Sandra C
authors.initials: SC
authors.lastname: Roerig
authors.forename: Philip S
authors.initials: PS
authors.lastname: Portoghese
mesh_terms: D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D004353:Drug Evaluation, Preclinical; D057809:HEK293 Cells; D006801:Humans; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D018345:Mice, Knockout; D009271:Naltrexone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000009:adverse effects / Q000494:pharmacology; D017473:Receptors, Opioid, kappa / Q000819:agonists* / Q000235:genetics / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000819:agonists* / Q000235:genetics / Q000378:metabolism
chemical_list: D000700:Analgesics; D009292:Narcotic Antagonists; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D009271:Naltrexone